Finerenone in Non-Diabetic CKD: FIND-CKD Explained
We break down the FIND-CKD trial and what it means for people with non-diabetic chronic kidney disease and proteinuria, focusing on finerenone’s impact on eGFR decline, kidney-related outcomes, and why an early dip in kidney function may not be a warning sign.
The episode also covers hyperkalemia risk, practical dose adjustment strategies, and the big question of how finerenone fits alongside ACE inhibitors, ARBs, and SGLT2 inhibitors in modern kidney care.
Chapter 1
Expanding the Mineralocorticoid Horizon Beyond Diabetes
Dr. James Whitfield
For years, literally years, if you had chronic kidney disease with spilling protein, but, uh, but you didn't have diabetes, we were essentially stuck. We had renin angiotensin system inhibitors, like ACE inhibitors or ARBs, and that was pretty much where the road ended. But then the FIND CKD trial came out in the New England Journal of Medicine, and it completely opens up non steroidal mineralocorticoid receptor antagonists, like finerenone, for this whole non diabetic population.
Dr. Elena Rodriguez
Non diabetic proteinuric kidney disease. That is a massive group of patients who were just left waiting on old therapies. So, James, how big was this trial to finally test finerenone there?
Dr. James Whitfield
It was fifteen hundred and eighty four adults. Exactly fifteen eighty four, randomized, double blind, placebo controlled, across adults with non diabetic chronic kidney disease. And, er, their baseline urinary albumin to creatinine ratio was a median of eight hundred and nineteen milligrams per gram. Their eGFR was between twenty five and under ninety mL per minute per one point seven three meters squared. And here is the crucial bit: ninety nine point seven percent of them were already on optimized RAS blockade.
Dr. Elena Rodriguez
Ninety nine point seven percent! So they weren't just comparing finerenone to nothing, they were testing it on top of maximum standard care. What did thirty two months of follow up actually show for eGFR slope?
Dr. James Whitfield
Right. Over thirty two months, finerenone led to a slower decrease in the eGFR than placebo over thirty two months. Specifically, the mean annual decline in eGFR was minus three point three mL per minute in the finerenone group versus minus four point zero mL per minute with placebo.
Dr. Elena Rodriguez
So, wait, minus three point three versus minus four point zero. That is a preservation of zero point seven mL per minute per year, right? P value less than zero point zero zero one.
Dr. James Whitfield
Zero point seven mL per minute per year saved, exactly. Confidence interval zero point three to one point one. It sounds modest on paper, but, uh, multiplied across years, that is substantial time off dialysis.
Dr. Elena Rodriguez
Well, and, and, and what caught my eye in the paper was the trajectory at the very beginning. When patients start finerenone, there is this initial hemodynamic drop, a little dip in eGFR. And I know clinicians sometimes panic when they see that initial drop and want to stop the drug immediately!
Dr. James Whitfield
Oh, absolutely. The classic knee jerk reaction is to hit the brakes the second creatinine bumps up.
Dr. Elena Rodriguez
But mechanically, it is the exact same phenomenon we see with SGLT2 inhibitors! When you block the mineralocorticoid receptor in the nephron, you reduce intraglomerular pressure. You relax that hyperfiltration. So that initial dip, far from being acute kidney injury, is actually proof of hemodynamic relief! You trade a tiny short term eGFR reduction for long term structural protection of the surviving nephrons.
Chapter 2
Hard Endpoints Hyperkalemia and Clinical Implementation
Dr. James Whitfield
That mechanism really grounds why the hard clinical endpoints moved too. In the prespecified hierarchical secondary outcome, which looked at a sustained drop in eGFR of fifty seven percent or more, kidney failure, heart failure hospitalization, or cardiovascular death, thirteen point nine percent of patients on finerenone hit that composite endpoint, compared to sixteen point nine percent on placebo. Hazard ratio zero point seven seven.
Dr. Elena Rodriguez
Zero point seven seven, so a twenty three percent relative risk reduction! But, er, was that driven by heart failure or by the kidney outcomes?
Dr. James Whitfield
It was overwhelmingly driven by kidney preservation. But, look, we have to talk about the side effect trade off, because blocking aldosterone signaling in the distal tubule comes with a price tag, and that price tag is serum potassium.
Dr. Elena Rodriguez
Right. Hyperkalemia. What were the actual safety numbers in FIND CKD?
Dr. James Whitfield
Hyperkalemia occurred in seventeen point zero percent of patients taking finerenone, compared to thirteen point three percent on placebo. But here is the thing: serious hyperkalemia was rare, just one point zero percent versus zero point six percent. And permanent drug discontinuation because of high potassium was only one point five percent.
Dr. Elena Rodriguez
One point five percent discontinuation! That is remarkably low for a trial where seventeen percent developed hyperkalemia. How did they keep people on the drug?
Dr. James Whitfield
Flexible dose modification protocols. They didn't just throw their hands up and stop the drug permanently at the first high potassium reading. They down titrated from twenty milligrams to ten milligrams, rechecked serum potassium, adjusted dietary intake, and restarted when appropriate. It shows that hyperkalemia is manageable if you have a routine monitoring protocol in place.
Dr. Elena Rodriguez
Though, James, I have to raise one big caveat about generalizability. Only seventeen percent of the participants in FIND CKD were on baseline SGLT2 inhibitors. Seventeen percent! In modern nephrology practice, flozins are becoming first line alongside RAS blockade. So if a patient is already on an SGLT2 inhibitor and an ACE inhibitor, do we get additive protection from adding finerenone, or are we hitting diminishing returns while compounding the lab monitoring burden?
Dr. James Whitfield
It, it, it is the million dollar clinical question right now. SGLT2 inhibitors actually tend to lower serum potassium slightly, so combining them with an nsMRA might theoretically blunt the hyperkalemia risk while giving dual nephroprotection. But, as you said, with only seventeen percent co use in this trial, we need dedicated combination data to know for sure.
Dr. Elena Rodriguez
Still, the conceptual shift here for outpatient primary care and nephrology is huge. For years, finerenone was framed strictly as a diabetic kidney disease drug.
Dr. James Whitfield
Exactly. The takeaway at the bedside changes completely now. Clinicians shouldn't be asking "does this CKD patient have diabetes?" anymore. The question is "does this patient have persistent albuminuria despite maximum tolerated RAS blockade?" If the answer is yes, finerenone is now a proven tool to slow down their progression.
Dr. Elena Rodriguez
Simple, actionable reframing. Well said, James.
Dr. James Whitfield
Alright, that is FIND CKD in a nutshell. Catch you next time.